Reports Q3 revenue $9.5M, consensus $10.02M. “We are pleased with our third quarter results led by record sales in our distributor territories, strong sales in our other direct markets, and improved operating margins and cash efficiencies across the company,” stated CEO Phillip Chan. “This strong sales growth was partially offset by a decline in our direct German market where we continue our proactive reorganization of our commercial team and selling approach which we believe will lead to improved performance and execution in 2026.”
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CTSO:
- CTSO Upcoming Earnings Report: What to Expect?
- Cytosorbents Corp’s Latest Study Update: A Game Changer in Critical Care?
- CytoSorbents’ STAR Registry: A Closer Look at the Latest Clinical Study Update
- Cytosorbents Faces Nasdaq Non-Compliance Notice
- CytoSorbents provides DrugSorb-ATR regulatory update